# Ajinomoto Co., Inc. 

## Consolidated Results

## Third Quarter Ended December 31, 2011

This document has been translated from the original Japanese as a guide for non-Japanese investors. It contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. Actual financial results may differ materially depending on a number of factors, including changing economic conditions, legislative and regulatory developments, delay in new product launches, and pricing and product initiatives of competitors.

## SUMMARY OF FINANCIAL STATEMENTS (Consolidated)

Third quarter results for the year ending March 31, 2012

| Ajinomoto Co., Inc. |  |  |  | January 31, 2012 |
| :---: | :---: | :---: | :---: | :---: |
| Stock Code:http://www.ajinomoto.com |  | exchanges: | Tokyo, Osaka |  |
|  |  | ies: | o Kobayashi |  |
| President: | Masatoshi Ito |  | General Manager |  |
| Scheduled date of submission of quarterly report: | February 10, 2012 |  | Finance Department |  |
| Creation of supplementary quarterly results materials: |  |  | Telephone: 813 5250-8161 |  |
| Quarterly results briefing: | No |  | Scheduled date of payment of dividend: N/A |  |
| 1. Consolidated Financial Results for the Nine Months Ended December 31, 2011 <br> 1) Consolidated Operating Results <br> Millions of yen, rounded dow |  |  |  |  |
|  |  |  |  |  |
|  | Nine months ended December 31, 2011 |  | Nine months ended December 31, 2010 |  |
|  |  | Change \% |  | Change \% |
| Net sales | 913,936 | (1.7) | 929,778 | 4.2 |
| Operating income | 66,865 | 1.8 | 65,706 | 11.1 |
| Ordinary income . | 69,951 | 4.6 | 66,875 | 6.2 |
| Net income | 41,995 | 28.7 | 32,623 | (12.4) |
| Net income per share ( $¥$ ). | $¥ 61.50$ |  | $¥ 46.75$ |  |
| Fully diluted earnings per share ( $¥$ ) .......... | -- -- |  | -- |  |
| Notes: "Change \%" indicates the percentage change compared to the previous fiscal year. Notes: Comprehensive income: |  |  |  |  |
| 2) Financial Position | Millions of yen, rounded down |  |  |  |
|  |  |  |  |  |
|  | As of December 31, 2011 |  | As of March 31, 2011 |  |
| Total assets | 1,050,321 |  | 1,077,418 |  |
| Net assets. | $\begin{array}{r} 623,703 \\ 55.5 \% \\ \hline \end{array}$ |  | 650,291 |  |
| Shareholders' equity ratio (\%) ..................... |  |  |  | 56.4\% |
| Note: Shareholders' equity | As of December 31, 2011: $¥ 582,953$ million |  | As of March 31, 2011: $¥ 608,191$ million |  |

## 2. Dividends

|  | FY ended March 31, 2011 | FY ending March 31, 2012 | FY ending March 31, 2012 (forecast) |
| :---: | :---: | :---: | :---: |
| Dividend per share (Record date) |  |  |  |
| End of first quarter....................... | -- | -- |  |
| End of second quarter.................. | ¥8.00 | $¥ 8.00$ |  |
| End of third quarter...................... | -- |  | -- |
| End of fourth quarter .................... | $¥ 8.00$ |  | $¥ 8.00$ |
| Annual ....................................... | ¥16.00 |  | ¥16.00 |

[^0]3. Forecast for the Fiscal Year Ending March 31, 2012

|  | Millions of yen, rounded down |  |
| :---: | :---: | :---: |
|  | FY Ending March 31, 2012 |  |
|  |  | Change \% |
| Net sales.. | 1,220,000 | 1.0 |
| Operating income . | 71,000 | 2.3 |
| Ordinary income ... | 72,000 | 2.1 |
| Net income ............................................. | 38,000 | 25.0 |
| Net income per share .............................. | 55.77 | -- |

Note: "Change \%" indicates the percentage change compared to the previous fiscal year.
Revisions to consolidated earnings forecasts in the period under review: No

## 4. Other

1) Transfer of important subsidiaries during the period (transfer of specified subsidiaries resulting in changes in the scope of consolidation): No
2) Adoption of special accounting methods for preparation of quarterly financial statements: Yes

For more information, see page 8, "2. SUMMARY INFORMATION (OTHER) (2) Adoption of special accounting methods for preparation of quarterly financial statements."
3) Changes in accounting policy, changes in accounting estimates, and retrospective restatements
(1) Changes in line with revision to accounting standards: No
(2) Other changes: No
(3) Changes in accounting estimates: No
(4) Retrospective restatements: No
4) Number of shares outstanding (ordinary shares)
(1) Number of shares outstanding at end of period (including treasury shares):

December 31, 2011: 678,980,654 March 31, 2011: 700,032,654 shares
(2) Number of treasury shares at end of period

December 31, 2011: 2,286,092 March 31, 2011: 2,255,060 shares
(3) Average number of shares during period

April 1, 2011 to December 31, 2011: 682,842,915 April 1, 2010 to December 31, 2010: 697,847,345 shares
*Status of implementation of quarterly review procedures
This quarterly kessan tanshin document is outside the scope of quarterly review procedures based on the Financial Instruments and Exchange Act. As of the time of its disclosure, quarterly review procedures with respect to the quarterly financial statements were in the process of being implemented.
*Forward-looking statements, such as business forecasts, made in these financial statements are based on management's estimates, assumptions and projections at the time of publication. A number of factors could cause actual results to differ materially from expectations. For more information regarding our business forecasts, see page 8, "1. QUALITATIVE INFORMATION ON NINE-MONTH PERIOD CONSOLIDATED RESULTS, (3) Qualitative information about consolidated earnings forecasts".
*Method of obtaining supplementary results materials
Supplementary results materials will be published on the Company's website on January 31, 2012.

Table of contents

1. QUALITATIVE INFORMATION ON NINE-MONTH PERIOD CONSOLIDATED RESULTS ..... 5
(1) Qualitative information about consolidated operating results ..... 5
(2) Qualitative information about consolidated financial position ..... 7
(3) Qualitative information about consolidated earnings forecasts ..... 8
2. SUMMARY INFORMATION (OTHER) ..... 8
(1) Transfer of important subsidiaries in the period under review ..... 8
(2) Adoption of special accounting methods for preparation of financial statements ..... 8
(3) Changes in accounting policy, changes in accounting estimates, and retrospective restatements ..... 8
3. CONSOLIDATED NINE-MONTH PERIOD FINANCIAL STATEMENTS ..... 9
(1) Consolidated balance sheet ..... 9
(2) Consolidated statement of income and consolidated statement of comprehensive income ..... 11
(3) Notes regarding premise of a going concern ..... 13
(4) Segment information ..... 13
(5) Notes regarding marked changes in amount of shareholders' equity ..... 15
(6) Other ..... 15

## 1. QUALITATIVE INFORMATION ON NINE-MONTH PERIOD CONSOLIDATED RESULTS

## (1) Qualitative information about consolidated operating results

Note: All comparisons are with same nine-month period of the previous fiscal year, unless stated otherwise.
In the nine-month period under review (April 1, 2011 to December 31, 2011), the recovery trend in the overall global economy weakened, despite moderate expansion in emerging markets, partly reflecting instability in financial markets due to the European debt crisis, as well as rising food and raw materials prices.

The Japanese economy gradually picked up after the declines in production and downturn in consumption due to the Great East Japan Earthquake, but uncertainties remain about the economy's full-scale future recovery, partly reflecting the impact of the nuclear power plant accident and ensuing electricity shortages, as well as the sharp appreciation of the yen and other factors

The environment in the Japanese food industry remained severe, with rising prices of raw materials for foods amid moderate deflation.

Within this environment, consolidated sales for the nine-month period decreased $1.7 \%$ ( $¥ 15.8$ billion) to $¥ 913.9$ billion, operating income increased $1.8 \%$ ( $¥ 1.1$ billion) to $¥ 66.8$ billion, ordinary income increased $4.6 \%$ ( $¥ 3.0$ billion) to $¥ 69.9$ billion, and net income increased $28.7 \%$ ( $¥ 9.3$ billion) to $¥ 41.9$ billion.

## Consolidated operating results by segment

Consolidated operating results by business segment are as follows:
Note: All comparisons are with same nine-month period of the previous fiscal year, unless stated otherwise.
Billions of yen, rounded down

|  | Bilions of yen, rounded down |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Net sales | YoY <br> change <br> -amount | YoY <br> change - <br> percent | Operating <br> income | YoY <br> change <br> -amount | YoY <br> change - <br> percent |
| Domestic food products | 339.6 | $(1.9)$ | $(0.6 \%)$ | 31.2 | 4.6 | $17.5 \%$ |
| Overseas food products | 172.6 | $(2.8)$ | $(1.6 \%)$ | 18.0 | $(4.8)$ | $(21.3 \%)$ |
| Bioscience products and | 145.8 | $(2.3)$ | $(1.6 \%)$ | 9.3 | 0.9 | $11.8 \%$ |
| fine chemicals | 61.0 | $(2.3)$ | $(3.8 \%)$ | 6.9 | $(0.8)$ | $(10.7 \%)$ |
| Pharmaceuticals | 141.0 | $(3.4)$ | $(2.4 \%)$ | 1.2 | 0.0 | $3.9 \%$ |
| Business tie-ups | 53.6 | $(2.9)$ | $(5.2 \%)$ | $(0.0)$ | 1.1 | -- |
| Other business | 913.9 | $(15.8)$ | $(1.7 \%)$ | 66.8 | 1.1 | $1.8 \%$ |
| Total |  |  |  |  |  |  |

Notes 1. Effective the first-quarter period of the fiscal year ending March 31, 2012, adjustment amounts have been allocated to each segment, and figures for the previous nine-month period have also been restated.
2. Effective the first-quarter period of the fiscal year ending March 31, 2012, domestic sales of amino acid supplement amino VITAL ${ }^{\circledR}$ are included in other business and domestic sales of low-calorie sweetener for home use and the restaurant market are included in bioscience products and fine chemicals.
3. Domestic and overseas sales of $A C T I V A^{\circledR}$ products to food processing companies and savory seasonings are included in domestic food products.
4. Frozen food products of the Amoy Food Group are classified in domestic food products.

## Domestic food products

Domestic food product sales decreased $0.6 \%$ ( $¥ 1.9$ billion) to $¥ 339.6$ billion, and operating income increased $17.5 \%$ ( $¥ 4.6$ billion) to $¥ 31.2$ billion. The slight decrease in sales was partly attributable to the impact of the earthquake. The substantial increase in operating income reflected a reduction in selling expenses and other factors.

Seasonings and processed foods: In seasonings and processed foods for the retail market, sales of Chinese dashi products and consommé increased favorably and HON-DASH ${ }^{\circledR}$ and the Cook Do ${ }^{\circledR}$ line increased steadily, while sales of soup products increased. Sales of umami seasoning AJI-NO-MOTO ${ }^{\circledR}$ were at the same level as the previous period, but sales of mayonnaise and mayonnaise-type dressings decreased slightly and Kellogg's ${ }^{\circledR}$ products decreased.

Sales of products for the commercial market increased steadily, with a recovery trend evident in consumer spending at restaurants since the earthquake. Sales of $A C T I V A^{\circledR}$, an enzyme (transglutaminase) used to enhance food texture and quality, to food processing companies declined in Japan and decreased slightly overseas due to increased competition with competitors. Sales of savory seasoning products decreased, as sales volumes declined, reflecting product shortages following the earthquake.

Delicatessen and bakery products: Sales of lunchboxes and prepared dish delicatessen products grew steadily, while sales of bakery products increased favorably.

Frozen foods: Sales of products for the retail market increased steadily, due to steady increases in sales of core products Gyoza and Puripuri-no-Ebi Shumai, favorable increases in Yawaraka Wakadori Kara-Age and rice products such as Fried rice with various ingredients, and sales of naturally defrosted lunchbox products such as Ebi-yose Fry becoming firmly established. Sales of products for restaurant and institutional use were at the same level as the previous nine-month period, with a recovery trend evident following a slump in the restaurant and catering market after the earthquake.

Beverages: Beverage sales decreased slightly.

## Overseas food products

Overseas food product sales decreased $1.6 \%$ ( $¥ 2.8$ billion) to $¥ 172.6$ billion, reflecting the impact of foreign exchange rates and other factors. Operating income decreased $21.3 \%$ ( $¥ 4.8$ billion) to $¥ 18.0$ billion, which was partly attributable the impact of foreign exchange rates and higher raw material prices.

Seasonings: In Asia, sales of $A J I-N O-M O T O^{\circledR}$ were at the same level as the previous nine-month period, while flavor seasonings for home use trended favorably. In the Americas, sales of flavor seasonings for home use in South America grew favorably. In Europe and Africa, sales of AJI-NO-MOTO ${ }^{\circledR}$ for home use in West African countries increased substantially.

Processed foods: In Asia, sales of powdered drink Birdy ${ }^{\circledR} 3$ in 1 grew strongly, while instant noodles also increased favorably. Sales of beverages such as Birdy ${ }^{\circledR}$ canned coffee were in line with the previous period.

Umami seasonings for processed food manufacturers: In Japan, sales volumes and sales of both AJI-NO-MOTO ${ }^{\circledR}$ for the food processing industry and nucleotides decreased due to the impact of the earthquake. Overseas, sales of $A J I-N O-M O T O^{\circledR}$ for the food processing industry decreased. Sales of nucleotides decreased considerably due to a decline in sales prices.

## Bioscience products and fine chemicals

Bioscience products and fine chemicals sales decreased $1.6 \%$ ( $¥ 2.3$ billion) to $¥ 145.8$ billion. Operating income increased $11.8 \%$ ( $¥ 0.9$ billion) to $¥ 9.3$ billion.

Feed-use amino acids: Sales of Threonine decreased, while Tryptophan decreased substantially, reflecting the impact of foreign exchange rates and other factors. However, sales volumes of Lysine grew favorably, leading to a substantial increase in sales, and as a result sales increased overall.

Amino acids for pharmaceuticals and foods: Sales decreased overall, despite a strong increase in sales in Europe, reflecting a decrease in sales in North America due to the impact of foreign exchange rates and a substantial decline in sales in Japan.

Sweeteners: Sales of low-calorie sweeteners for home use and the restaurant market increased slightly from the previous period. Sales of powdered juice Refresco MID ${ }^{\circledR}$, which contains aspartame, in South America decreased, impacted by foreign exchange rates, and sales of aspartame, a sweetener, for the processing industry decreased, impacted by a decline in sales volumes as well as foreign exchange rates, and as a result sales decreased overall.

Pharmaceutical fine chemicals: Sales decreased compared to the nine-month period of the previous fiscal year.

Specialty chemicals: Sales of cosmetic ingredients increased slightly in Japan and also grew favorably overseas. However, sales of the amino acid-based cosmetics brand Jino ${ }^{\circledR}$ decreased, while sales of insulation film for build-up printed wiring board decreased significantly on a decline in sales volumes, and sales decreased as a result.

## Pharmaceuticals

Pharmaceutical sales decreased $3.8 \%$ ( $¥ 2.3$ billion) to $¥ 61.0$ billion, and operating income decreased $10.7 \%$ ( $¥ 0.8$ billion) to $¥ 6.9$ billion. Royalty income increased substantially, while self-distributed product sales decreased due to sluggish sales of core products, and sales of products sold through business tie-ups also decreased, resulting in a slight decline in overall sales. The decrease in overall operating income was partly attributable to a decline in sales and an increase in selling expenses, despite an increase in royalty income, cost-cutting initiatives and other factors.

For self-distributed products, sales of ELENTAL ${ }^{\circledR}$, an elemental diet, were at the same level as the previous period, but sales of $L I V A C T^{\circledR}$, a branched-chain amino acids formula for the treatment of liver cirrhosis, declined, and sales of infusions such as SOLITA ${ }^{\circledR}-T$, an electrolyte solution, decreased.

For products sold through business tie-ups, sales of risedronate such as ACTONEL ${ }^{\circledR}$, a preparation used in the treatment of osteoporosis, and ATELEC ${ }^{\circledR}$, an antihypertensive calcium channel blocker, were at the same level as the previous period, and sales of natiglinide such as non-insulin-dependent diabetes treatment FASTIC ${ }^{\circledR}$ declined substantially.

## Business tie-ups

Business tie-up sales decreased $2.4 \%$ ( $¥ 3.4$ billion) to $¥ 141.0$ billion. Operating income increased $3.9 \%$ ( $¥ 45$ million) to $¥ 1.2$ billion.

Edible oils: Sales decreased on a decline in sales volumes.

Coffee products: Coffee product sales increased slightly.

## Other business

Other business sales decreased $5.2 \%$ ( $¥ 2.9$ billion) to $¥ 53.6$ billion. Operating loss decreased $¥ 1.1$ billion to ¥27 million.

## (2) Qualitative information about consolidated financial position

Total assets as of December 31,2011 were $¥ 1,050.3$ billion, $¥ 27.0$ billion less than the $¥ 1,077.4$ billion
recorded at the end of the previous fiscal year. The key factor contributing to this decrease was a decline in the yen values of the balance sheets of overseas subsidiaries after translation.

Total interest-bearing debt decreased $¥ 2.6$ billion compared to the end of the previous fiscal year to $¥ 130.7$ billion.

Net assets decreased $¥ 26.5$ billion compared to the end of the previous fiscal year, despite an increase in retained earnings, influenced by factors such as a change in foreign exchange translation adjustments and a decrease in capital surplus on the retirement of treasury stock. Shareholders' equity, which is net assets minus minority interests, was $¥ 582.9$ billion, and the shareholders' equity ratio was $55.5 \%$.
(3) Qualitative information about consolidated earnings forecasts

No changes have been made to the full-year forecasts that the Company announced on November 4, 2011.

## 2. SUMMARY INFORMATION (OTHER)

(1) Transfer of important subsidiaries in the period under review:

No applicable items.

## (2) Adoption of special accounting methods for preparation of financial statements:

Method of estimating tax expenses
The Company and its consolidated subsidiaries estimate tax expenses by making a reasonable estimation of the effective tax rate on net income before income taxes after the application of tax effect accounting for the fiscal year, including the nine-month period under review, and applying this rate to net income before income taxes for the nine-month period under review. However, for subsidiaries for which calculating tax expenses using an estimation of the effective tax rate would significantly lack rationality, tax expenses are estimated by using the statutory effective tax rate and factoring in material additions or deductions.
(3) Changes in accounting policy, changes in accounting estimates, and retrospective restatements: No applicable items.

## 3. CONSOLIDATED NINE MONTH-PERIOD FINANCIAL STATEMENTS

(1) Consolidated balance sheet

|  | Millions of yen, rounded down |  |
| :---: | :---: | :---: |
|  | As of end of third quarter (December 31, 2011) | As of end of previous fiscal year (March 31, 2011) |
| ASSETS |  |  |
| Current assets |  |  |
| Cash on hand and in banks. | 123,301 | 141,801 |
| Notes and accounts receivable.. | 217,186 | 195,465 |
| Marketable securities . | 460 | 511 |
| Goods and products | 90,180 | 87,445 |
| Goods in process. | 8,420 | 7,370 |
| Raw materials and supplies .. | 39,410 | 40,495 |
| Deferred tax assets. | 12,579 | 11,204 |
| Other., | 31,260 | 33,376 |
| Allowance for doubtful accounts .......... | $(1,075)$ | $(1,238)$ |
| Total current assets ....................... | 521,724 | 516,432 |
| Fixed assets |  |  |
| Tangible fixed assets |  |  |
| Buildings and structures ..... | 339,747 | 350,654 |
| Accumulated depreciation and accumulated impairment losses. | $(207,110)$ | $(209,127)$ |
| Net buildings and structures............... | 132,636 | 141,527 |
| Machinery and vehicles ............ | 488,672 | 508,083 |
| Accumulated depreciation and accumulated impairment losses $\qquad$ | $(381,932)$ | $(391,574)$ |
| Net machinery and vehicles ......... | 106,740 | 116,509 |
| Land. | 95,968 | 98,167 |
| Construction in progress. | 19,959 | 19,013 |
| Other. | 69,828 | 69,345 |
| Accumulated depreciation and accumulated impairment losses | $(57,982)$ | $(56,513)$ |
| Net other ........................................ | 11,846 | 12,832 |
| Total tangible fixed assets. | 367,150 | 388,050 |
| Intangible fixed assets |  |  |
| Goodwill. | 26,202 | 29,586 |
| Other.............................................. | 33,632 | 35,901 |
| Total intangible fixed assets ............... | 59,835 | 65,488 |
| Investments and other assets |  |  |
| Investment in securities ... | 81,272 | 83,105 |
| Long-term loans receivable.. | 1,038 | 1,060 |
| Deferred tax assets.. | 7,784 | 10,090 |
| Other.. | 12,581 | 14,443 |
| Allowance for doubtful accounts. | (814) | (988) |
| Allowance for investment losses .... | (251) | (264) |
| Total investment and other assets....... | 101,610 | 107,447 |
| Total fixed assets ........................... | 528,597 | 560,986 |
| Total Assets....................................... | 1,050,321 | 1,077,418 |

(Continued)

|  | Millions of yen, rounded down |  |
| :---: | :---: | :---: |
|  | As of end of third quarter (December 31, 2011) | As of end of previous fiscal year (March 31, 2011) |
| LIABILITIES |  |  |
| Current liabilities |  |  |
| Notes and accounts payable. | 114,429 | 103,420 |
| Short-term debt. | 17,881 | 16,209 |
| Current portion of long-term debt. | 4,682 | 5,316 |
| Accrued income taxes | 12,741 | 7,900 |
| Bonus reserve. | 3,477 | 6,784 |
| Bonus reserve for directors and others.. | 232 | 360 |
| Asset retirement obligations.. | -- | 64 |
| Other................................................ | 69,726 | 78,286 |
| Total current liabilities ........................ | 223,171 | 218,341 |
| Long-term liabilities |  |  |
| Bonds. | 69,990 | 69,989 |
| Long-term debt | 35,746 | 39,282 |
| Deferred tax liabilities . | 12,461 | 15,591 |
| Accrued employees' retirement benefits. $\qquad$ | 61,132 | 58,554 |
| Accrued officers' severance benefits .. | 1,000 | 1,331 |
| Allowance for environmental measures . | 572 | 574 |
| Allowance for loss on guarantees . | 183 | -- |
| Asset retirement obligations. | 579 | 540 |
| Other................................................ | 21,779 | 22,920 |
| Total long-term liabilities .................... | 203,446 | 208,786 |
| Total liabilities................................ | 426,618 | 427,127 |
| NET ASSETS |  |  |
| Shareholders' equity |  |  |
| Common stock. | 79,863 | 79,863 |
| Capital surplus . | 162,381 | 182,716 |
| Retained earnings. | 444,915 | 414,189 |
| Treasury stock | $(2,207)$ | $(2,514)$ |
| Total shareholders' equity................. | 684,953 | 674,255 |
| Accumulated other comprehensive income (loss) |  |  |
| Unrealized holding gain on securities .... | 234 | 1,339 |
| Unrealized gain from hedging instruments | 3 | (31) |
| Translation adjustments.................... | $(101,964)$ | $(67,045)$ |
| Adjustment in pension liabilities of overseas subsidiaries. | (273) | (327) |
| Total accumulated other comprehensive income (loss) | $(102,000)$ | $(66,064)$ |
| Minority interests.......................... | 40,749 | 42,099 |
| Total net assets. | 623,703 | 650,291 |
| Total Liabilities and Net Assets ........... | 1,050,321 | 1,077,418 |

(2) Consolidated statement of income

|  | Millions of yen, rounded down |  |
| :---: | :---: | :---: |
|  | Nine-month period (April 1, 2011 to <br> December 31, 2011) | Nine-month period (April 1, 2010 to December 31, 2010) |
| Net sales. | 913,936 | 929,778 |
| Cost of sales ................................................................. | 601,307 | 614,805 |
| Gross profit .................................................................. | 312,629 | 314,972 |
| Selling, general and administrative expenses ....................... | 245,763 | 249,266 |
| Operating income...................................................... | 66,865 | 65,706 |
| Non-operating income |  |  |
| Interest received | 1,354 | 874 |
| Dividend income ............................................ | 942 | 872 |
| Equity in earnings of non-consolidated subsidiaries and affiliates. | 2,042 | 2,514 |
| Other........................................................................... | 2,408 | 2,245 |
| Total non-operating income........................................ | 6,748 | 6,506 |
| Non-operating expenses |  |  |
| Interest expense | 1,658 | 1,911 |
| Exchange losses. | -- | 977 |
| Other........................................................................... | 2,003 | 2,449 |
| Total non-operating expenses .................................... | 3,662 | 5,337 |
| Ordinary income........................................................ | 69,951 | 66,875 |
| Extraordinary gains |  |  |
| Gain on sale of investment in securities | 332 | 913 |
| Insurance income | 3,083 | 1 |
| Other........................................................................... | 659 | 1,015 |
| Total extraordinary income.......................................... | 4,075 | 1,930 |
| Extraordinary losses |  |  |
| Loss on devaluation of securities. | 758 | 6,458 |
| Loss from natural disaster.. | 3,337 | -- |
| Other.......................................................................... | 3,008 | 3,553 |
| Total extraordinary losses .......................................... | 7,103 | 10,011 |
| Net income before income taxes....................................... | 66,923 | 58,794 |
| Income taxes ................................................................. | 20,437 | 21,610 |
| Net income before minority interests................................... | 46,486 | 37,183 |
| Minority interests ............................................................. | 4,490 | 4,560 |
| Net income................................................................... | 41,995 | 32,623 |

Consolidated Statement of Comprehensive Income

|  | Millions of yen, rounded down |  |
| :--- | ---: | ---: | \(\left.\begin{array}{c}Nine-month period <br>

(April 1, 2010 to\end{array}\right)\)
(3) Notes regarding premise of a going concern

No applicable items

## (4) Segment information

I. Nine-month period of the fiscal year ending March 31, 2012 (April 1, 2011 - December 31, 2011)

1. Information on sales and income or loss by reporting segment

|  | Millions of yen, rounded down |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Reporting segment |  |  |  |  | Other Business*1 | Adjustment amount | Consolidated |
|  | Domestic <br> Food <br> Products | Overseas <br> Food <br> Products | Bioscience Products and Fine Chemicals | Pharmaceuticals | Business Tie-ups |  |  |  |
| Sales |  |  |  |  |  |  |  |  |
| (1) Sales to third parties....... | 339,654 | 172,667 | 145,848 | 61,043 | 141,049 | 53,673 | -- | 913,936 |
| (2) Intra-group sales and transfers $\qquad$ | 3,862 | 5,307 | 4,195 | 77 | 251 | 49,247 | $(62,943)$ | -- |
| Total sales ................. | 343,517 | 177,974 | 150,044 | 61,121 | 141,300 | 102,920 | $(62,943)$ | 913,936 |
| Segment income (loss) <br> (Operating income (loss))... | 31,287 | 18,012 | 9,369 | 6,986 | 1,237 | (27) | -- | 66,865 |

Notes 1. Other Business includes the wellness business, the packaging business, the logistics business and other service businesses.

## 2. Changes to reporting segments

In response to changes to internal administrative systems at the Company, effective the first-quarter period of the fiscal year ending March 31, 2012 changes have been made to the method used to calculate income or loss by reporting segment.
The main points of change are: the discontinuation of the system under which quasi-royalties/quasi-commissions were borne by each reporting segment in accordance with its sales; the change in the reporting segment for recording the amount allocated to inventory with respect to cost variances under the standard cost accounting system adopted by the Company and the adjustment amount with respect to reporting segments recording adjustments to valuation of inventory at the Company; the allocation to each reporting segment, proportionally to sales, total assets and number of employees, of shared company-wide expenses including expenses associated with the Company's administrative divisions and expenses associated with some research facilities.
A restatement of the figures for last year based on the new calculation method is presented in "II. Nine-month period of the fiscal year ended March 31, 2011 (April 1, 2010 - December 31, 2010), 1. Information on sales and income or loss by reporting segment."

## 3. Information by region

|  | Millions of yen, rounded down |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | "Japan" |  | "Asia" | "Americas" | "Europe" | Total |
| Sales .................................................. | 613,619 | 149,338 | 87,285 | 63,693 | 913,936 |  |
| Percentage of total consolidated sales ....... | $67.1 \%$ | $16.3 \%$ | $9.6 \%$ | $7.0 \%$ | $100.0 \%$ |  |

Notes 1. Sales are based on the location of customers, and are classified by country or region.

## 4. Information on fixed assets, impairment losses and goodwill by reporting segment

No material occurrences or changes in the nine-month period under review.
II. Nine-month period of the fiscal year ended March 31, 2011 (April 1, 2010 - December 31, 2010)

1. Information on sales and income or loss by reporting segment

|  | Millions of yen, rounded down |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Reporting segment |  |  |  |  | Other Business*1 | Adjustment amount | Consolidated |
|  | Domestic <br> Food <br> Products | Overseas <br> Food <br> Products | Bioscience <br> Products and Fine Chemicals | Pharmaceuticals | Business Tie-ups |  |  |  |
| Sales |  |  |  |  |  |  |  |  |
| (1) Sales to third parties........ | 341,581 | 175,476 | 148,224 | 63,431 | 144,452 | 56,612 | -- | 929,778 |
| (2) Intra-group sales and transfers $\qquad$ | 4,724 | 5,205 | 4,500 | $94$ | $168$ | $45,566$ | $(60,259)$ | -- |
| Total sales .................. | 346,305 | 180,682 | 152,724 | 63,525 | 144,620 | 102,178 | $(60,259)$ | 929,778 |
| Segment income (loss) <br> (Operating income (loss)).... | 26,633 | 22,883 | 8,379 | 7,827 | 1,191 | $(1,209)$ | -- | 65,706 |

Notes 1. Other Business includes the wellness business, the packaging business, the logistics business and other service businesses.
2. Segment income is restated based on the new calculation method. For details on the changes in the calculation method, please see "I. Nine-month period of the fiscal year ending March 31, 2012 (April 1, 2011 - December 31, 2011), 2. Changes to reporting segments".

## 2. Information by region

|  | Millions of yen, rounded down |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | "Japan" | "Asia" | "Americas" | "Europe" | Total |
| Sales .................................................... | 629,258 | 147,786 | 88,026 | 64,706 | 929,778 |
| Percentage of total consolidated sales ....... | 67.7\% | 15.9\% | 9.5\% | 6.9\% | 100.0\% |

Notes 1. Sales are based on the location of customers, and are classified by country or region.

## 3. Information on fixed assets, impairment losses and goodwill by reporting segment

No material occurrences or changes in the previous nine-month period.

## (Reference)

## Segment information by geographical area

Nine-month period of the fiscal year ending March 31, 2012 (April 1, 2011 to December 31, 2011)
Millions of yen, rounded down

|  | Millions of yen, rounded down |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | "Japan" | "Asia" | "Americas" | "Europe" | Consolidated |
| Sales to third parties ................................ | 630,404 | 133,124 | 86,059 | 64,348 | 913,936 |
| Operating income.................................... | 37,588 | 17,672 | 6,900 | 4,704 | 66,865 |

Nine-month period of the fiscal year ended March 31, 2011 (April 1, 2010 to December 31, 2010)

|  | Millions of yen, rounded down |  |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | :---: | :---: |
|  | "Japan" |  | "Asia" | "Americas" | "Europe" |  | Consolidated |
| Sales to third parties ........................... | 647,647 | 132,491 |  | 64,853 | 929,778 |  |  |
| Operating income.................................. | 34,526 | 18,223 | 6,252 | 6,703 | 65,706 |  |  |

Notes 1. Geographical area segments are categorized on the basis of geographic proximity and indicated in inverted commas.
2. Main countries and regions in segments other than "Japan":
"Asia": Countries of East and Southeast Asia
"Americas": Countries of North and South America
"Europe": Countries of Europe and Africa
3. In response to changes to internal administrative systems at the Company, changes have been made to the method used to calculate profit and loss by geographical area segment. The "adjustment amount" is allocated to each geographical area segment by calculating the ratio of net income, total assets and the number of employees.

## (5) Notes regarding marked changes in amount of shareholders' equity

The Company resolved at a meeting of the Board of Directors on May 9, 2011 on matters pertaining to a share repurchase based on Article 156 of the Companies Act as applied pursuant to Article 165-3 of the same act. Subsequently, in the period from May 10 until July 15, 2011 the Company repurchased, in the market through a trust bank, $21,052,000$ shares of common stock for $¥ 19,999$ million.

The Company resolved at a meeting of the Board of Directors on August 30, 2011 on matters pertaining to the retirement of shares based on Article 178 of the Companies Act. Subsequently, on September 16, 2011, the Company retired $21,052,000$ shares of common stock. As a result, capital surplus and treasury shares each decreased by $¥ 20,334$ million.
The total number of outstanding shares became 678,980,654.

## (6) Other

The extensive flooding in Thailand had impacts including the suspension of operations of some production plants producing beverages, frozen foods and other products, but as a result of the prompt shift of production to alternative plants and other measures, the impact on operating income was limited. While an extraordinary loss of approximately $¥ 2.0$ billion was recorded in respect of resulting damage, the Company had damage insurance covering assets including inventory, fixed assets and others.


[^0]:    Note: Revisions to dividend forecasts in the period under review: No

